Form 4: Director Richard Pops Exercises NBIX Stock Units

Neurocrine Biosciences Director Richard Pops acquired 3,318 shares of common stock through the vesting of restricted stock units.

Summary

• Director Richard Pops exercised 3,318 restricted stock units (RSUs) on May 21, 2026.
• The RSUs converted into common stock on a one-for-one basis at a price of $0.
• Following the transaction, the reporting person holds a total of 37,798 shares of Neurocrine Biosciences common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the standard vesting of previously granted equity compensation to a director.

Positives

• The transaction reflects the vesting of equity compensation, aligning director interests with shareholder outcomes.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine insider transaction filing.

Industry Context

StockSavvy.ai notes that routine equity vesting for board members is standard corporate governance practice in the biotechnology sector, indicating no change in strategic direction or insider sentiment.

Comparison to Industry Standards

• The transaction follows standard industry practices for director compensation and equity vesting schedules.
• The reporting person's ownership level remains consistent with typical non-executive director holdings in mid-to-large cap biotech firms.

Stakeholder Impact

• No material impact on shareholders, employees, or creditors.

Next Steps

• None identified.

Key Dates

Keywords

NBIX, Neurocrine Biosciences, Form 4, Insider Transaction, Equity Vesting, Director Ownership